OpenOnco · Treatment Plan

Treatment plan — Low-grade glioma

PLAN-COVERAGE-LGG-001-V1 · v1 · 2026-05-12

Patient

COVERAGE-LGG-001 · Algorithm: ALGO-GLIOMA-LGG-1L

DiagnosisLow-grade glioma

MOH / ICD-10C71

ICD-O-39400/3; C71

Clinical significance of mutations (ESCAT)

Tumor-board context — the engine does not use these tiers to rank tracks

✅ Covered biomarkers (matched in KB)

Biomarker	Variant	ESCAT	Evidence	Clinical significance	Drugs	Sources
No clinically actionable variants matched in this profile.

⚠️ Not included in plan

Biomarker	Status
BIO-IDH-MUTATION	BIO definition in KB; no ESCAT BMA entry — verify with clinician
BIO-1P19Q-CODELETION	BIO definition in KB; no ESCAT BMA entry — verify with clinician

Primary current-line option

Aggressive plan

★ DEFAULT

Indication

IND-GLIOMA-LOW-GRADE-1L-RT-PCV

Regimen

Radiotherapy + PCV (procarbazine/lomustine/vincristine) — high-risk low-grade glioma

Drugs + NSZU

Procarbazine (DRUG-PROCARBAZINE) 60 mg/m² PO days 8-21 of each cycle · q6w (42-day cycles) × 6 cycles · PO ✗ Not registered in UA
Lomustine (DRUG-LOMUSTINE) 110 mg/m² PO day 1 of each cycle · q6w × 6 cycles · PO ✗ Not registered in UA
Vincristine (DRUG-VINCRISTINE) 1.4 mg/m² IV (cap 2 mg) days 8 and 29 of each cycle · q6w × 6 cycles · IV ⚠ NSZU — not for this indication

Reason

Primary current-line option selected by ALGO-GLIOMA-LGG-1L at step 3.

What NOT to do

Explicit prohibitive rules, each grounded in a regimen / supportive care / contraindication entity

Aggressive plan (IND-GLIOMA-LOW-GRADE-1L-RT-PCV)

Do not skip molecular profiling (IDH1/2, 1p/19q, ATRX, MGMT, CDKN2A) — defines grade per WHO 5th ed. and choice of adjuvant
Do not prescribe RT+PCV to patients with IDH-wildtype LGG — reclassify to GBM, requires Stupp protocol
Do not start PCV without baseline LFTs, CBC + contraception (procarbazine teratogen + EtOH-disulfiram-like reaction)
Do not skip levetiracetam-based AED in patients with seizures — does not induce P450, unlike phenytoin/carbamazepine

Timeline

Treatment timeline — derived from regimen + monitoring schedule

Aggressive plan

Induction · Radiotherapy + PCV (procarbazine/lomustine/vincristine) — high-risk low-grade glioma

42-day cycles × 6 cycles adjuvant (after RT 54 Gy/30 fx)

MDT brief

Discussion questions (1, 0 blocking)

OQ-LDH-CURRENT
What is the current LDH? Marker of tumor burden and transformation.
LDH is part of the prognostic indices of indolent lymphomas.
→ hematologist

MDT talk tree (3 steps)

#	Owner	Topic	Action
1	hematologist	Staging / disease burden	What is the current LDH? Marker of tumor burden and transformation.
2	clinical_pharmacist	Specialist review	Chemoimmunotherapy regimen — drug-drug interactions, dose adjustments, premedication.
3	molecular_geneticist	Specialist review	Indication references an actionable genomic biomarker — mutation / target / actionability interpretation needed.

Skills (recommended) — for consideration (2)

Clinical pharmacist recommended
Chemoimmunotherapy regimen — drug-drug interactions, dose adjustments, premedication.
Molecular geneticist / molecular oncologist recommended
Indication references an actionable genomic biomarker — mutation / target / actionability interpretation needed.

Data quality

Usable with caveats. No critical default-track gap was found, but the MDT should review the listed caveats before final sign-off.

Biomarker coverage: 1/1 known (100%), 0 missing, 0 default-track gaps
Unevaluated RedFlags: RF-GLIOMA-LOW-GRADE-FRAILTY-AGE, RF-GLIOMA-LOW-GRADE-HIGH-RISK-BIOLOGY, RF-GLIOMA-LOW-GRADE-INFECTION-SCREENING, RF-GLIOMA-LOW-GRADE-INTRACRANIAL-PRESSURE, RF-GLIOMA-LOW-GRADE-ORGAN-DYSFUNCTION, RF-GLIOMA-LOW-GRADE-TRANSFORMATION-PROGRESSION

Technical MDT skill metadata (2/16 activated in this plan)

All registered virtual specialists. ✓ — activated for this case; ○ — not activated (available for other clinical scenarios).

Specialist	skill_id	Version	Last reviewed	Domain
Cellular therapy specialist (CAR-T)	`cellular_therapy_specialist`	v0.1.0	2026-04-25	cellular_therapy
Clinical pharmacist	`clinical_pharmacist`	v0.1.0	2026-04-25	clinical_pharmacy
Hematologist / oncohematologist	`hematologist`	v0.1.0	2026-04-25	hematology_oncology
Hematopathologist (lymphoma / leukemia / myeloma)	`hematopathologist`	v0.1.0	2026-04-25	hematopathology
Infectious disease / hepatology	`infectious_disease_hepatology`	v0.1.0	2026-04-25	infectious_diseases
Medical oncologist (solid-tumor chemotherapist)	`medical_oncologist`	v0.1.0	2026-04-25	solid_oncology
Molecular geneticist / molecular oncologist	`molecular_geneticist`	v0.1.0	2026-04-25	molecular_oncology
Palliative care	`palliative_care`	v0.1.0	2026-04-25	palliative_care
Pathologist (general)	`pathologist`	v0.1.0	2026-04-25	pathology
Primary care / family physician	`primary_care`	v0.1.0	2026-04-25	primary_care
Psycho-oncologist	`psychologist`	v0.1.0	2026-04-25	psychosocial
Radiation oncologist	`radiation_oncologist`	v0.1.0	2026-04-25	radiation_oncology
Radiologist	`radiologist`	v0.1.0	2026-04-25	diagnostic_imaging
Social worker / case manager	`social_worker_case_manager`	v0.1.0	2026-04-25	psychosocial
Surgical oncologist	`surgical_oncologist`	v0.1.0	2026-04-25	surgical_oncology
Transplant specialist (BMT)	`transplant_specialist`	v0.1.0	2026-04-25	cellular_therapy

Sources cited

SRC-EANO-GBM-2024: EANO Guidelines on Diagnosis and Treatment of Diffuse Gliomas of Adulthood (2024 update)
SRC-NCCN-CNS-2025: NCCN Central Nervous System Cancers (v.3.2025)

Experimental options (clinical trials)

Third plan track — open-enrollment trials from ClinicalTrials.gov. Render-time metadata; engine selection is not affected by this block (CHARTER §8.3). Last synced: 2026-05-12.

NCT	Title	Phase	Status	Sponsor	UA	Signals
NCT01649830	Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma	PHASE3	RECRUITING	Sun Yat-sen University	—	Surrogate endpoint only Single country
NCT06132685	Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial	PHASE2	RECRUITING	Emory University	—	Single country
NCT04775485	A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors	PHASE2	RECRUITING	Day One Biopharmaceuticals, Inc.	—	Surrogate endpoint only
NCT06159478	Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume)	PHASE2	RECRUITING	National Cancer Center, Japan	—	Small N (<50) Surrogate endpoint only Single country
NCT04859725	HyperSpectral Imaging in Low Grade Glioma	NA	RECRUITING	Universitaire Ziekenhuizen KU Leuven	—	Small N (<50) Single country
NCT05133154	LIQUID BIOPSY IN Low-grade Glioma Patients	NA	RECRUITING	University Hospital, Montpellier	—	Single country
NCT07042620	A Study to Test a New Fluid to Improve the Quality of Images Obtained by Using Sound Waves (Ultrasound) During Surgery	NA	RECRUITING	SonoClear AS	—	Small N (<50) Single country
NCT02691923	Diagnostic Performance of Fluorescein as an Intraoperative Brain Tumor Biomarker	PHASE2	RECRUITING	David W. Roberts	—	Small N (<50) Single country
NCT06636162	Window of Opportunity Study of DSP-0390 in Gliomas	EARLY_PHASE1	RECRUITING	Washington University School of Medicine	—	Small N (<50) Single country
NCT03975829	Pediatric Long-Term Follow-up and Rollover Study	PHASE4	RECRUITING	Novartis Pharmaceuticals	—	—

Verify recruitment status directly with the trial site. ctgov data can lag behind current UA-site status.

Option availability in Ukraine

Per-track UA registration · NSZU · cost · access pathway. Render-time metadata; engine selection does not depend on these fields (CHARTER §8.3).

Option	UA registration	NSZU	Cost orientation	Access pathway
Aggressive plan Radiotherapy + PCV (procarbazine/lomustine/vincristine) — high-risk low-grade glioma (REG-RT-PCV-LGG) 2/3 component drug(s) not registered in Ukraine +1	✗ not registered	✗ out-of-pocket	₴-? — verify pathway	not recorded
Trial · NCT01649830 Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT06132685 Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT04775485 A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT06159478 Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume) No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT04859725 HyperSpectral Imaging in Low Grade Glioma No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT05133154 LIQUID BIOPSY IN Low-grade Glioma Patients No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT07042620 A Study to Test a New Fluid to Improve the Quality of Images Obtained by Using Sound Waves (Ultrasound) During Surgery No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT02691923 Diagnostic Performance of Fluorescein as an Intraoperative Brain Tumor Biomarker No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT06636162 Window of Opportunity Study of DSP-0390 in Gliomas No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT03975829 Pediatric Long-Term Follow-up and Rollover Study No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor

Cost information is orientation. Verify with a specific pharmacy / foundation / trial site. Status updated: 2026-05-12.

plan_id: PLAN-COVERAGE-LGG-001-V1 | version: 1 | generated: 2026-05-12T18:41:26.039043+00:00

Per FDA non-device CDS positioning (CHARTER §15): Outpatient oncology treatment planning to support tumor-board discussion. Not a medical device; not for autonomous clinical decision-making.

Per FDA non-device CDS positioning (CHARTER §15): Both treatment options below are presented for review. The engine's selection of a 'recommended' default does not constitute a clinical decision. Final treatment selection requires HCP judgment incorporating information not available to the system.

This document is an informational resource supporting tumor-board discussion (per CHARTER §11). It is not a system that makes clinical decisions. Every recommendation must be verified by the treating physician.